Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGIO
  • CUSIP:
Key Metrics:
  • Previous Close: $54.09
  • 50 Day Moving Average: $43.80
  • 200 Day Moving Average: $47.78
  • 52-Week Range: $34.31 - $67.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.75
  • P/E Growth: 0.00
  • Market Cap: $2.13B
  • Outstanding Shares: 42,234,000
  • Beta: 1.97
  • Net Margins: -341.56%
  • Return on Equity: -53.39%
  • Return on Assets: -35.70%
  • Current Ratio: 7.70%
  • Quick Ratio: 7.70%
Additional Links:
Companies Related to Agios Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 3 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $63.90 (26.79% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateFirmActionRatingPrice TargetDetails
2/16/2017Canaccord GenuitySet Price TargetBuy$90.00View Rating Details
2/16/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$75.00View Rating Details
2/16/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/16/2017Janney Montgomery ScottUpgradeNeutral -> Buy$57.00View Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformView Rating Details
1/17/2017CannUpgradeMarket Perform -> Outperform$75.00View Rating Details
12/19/2016Leerink SwannReiterated RatingMarket Perform$56.00 -> $45.00View Rating Details
12/16/2016Needham & Company LLCReiterated RatingBuy$60.00 -> $54.00View Rating Details
11/21/2016Credit Suisse GroupReiterated RatingBuyView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralView Rating Details
8/10/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$46.00View Rating Details
6/13/2016J P Morgan Chase & CoUpgradeNeutral -> Overweight$50.00 -> $62.00View Rating Details
5/18/2016SunTrust Banks, Inc.Boost Price TargetBuy$57.00 -> $65.00View Rating Details
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00View Rating Details
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00View Rating Details
7/2/2015DesjardinsUpgradeHold -> BuyView Rating Details
6/2/2015Citigroup Inc.Initiated CoverageNeutral$132.00View Rating Details
5/8/2015MLV & Co.Initiated CoverageBuy$130.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.50)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.92)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.58)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 millionViewListenView Earnings Details
8/7/2014Q2($0.41)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.38)($0.39)ViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
Current Year EPS Consensus Estimate: $-5.81 EPS
Next Year EPS Consensus Estimate: $-5.76 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.48)($0.52)
Q2 20163($1.33)($1.15)($1.23)
Q3 20163($1.42)($1.26)($1.32)
Q4 20164($1.49)($0.91)($1.21)
Q1 20172($1.78)($0.91)($1.35)
Q2 20172($1.91)($1.54)($1.73)
Q3 20171($1.61)($1.61)($1.61)
Q4 20171($1.73)($1.73)($1.73)
(Data provided by Zacks Investment Research)


Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 88.79%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.00View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.00View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline logoAgios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017 (NASDAQ:AGIO) - February 21 at 3:39 PM
News IconToday Analysts Focus on FLIR Systems, Inc. (FLIR), Agios Pharmaceuticals, Inc. (AGIO) - StockNewsJournal (NASDAQ:AGIO) - February 21 at 6:26 AM
News IconABR Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock At 1.38 - Stock Observer (NASDAQ:AGIO) - February 20 at 6:19 AM
News IconAgios Pharmaceuticals Inc AGIO Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:AGIO) - February 19 at 3:19 PM
News IconThe Bears And Bulls Square Off On Agios Pharmaceuticals, Inc. (AGIO) - NY Stock News (NASDAQ:AGIO) - February 18 at 9:30 AM
News IconAverage Brokerage Rating Of Convergys Corporation (CVG), Agios ... - The USA Commerce (NASDAQ:AGIO) - February 18 at 9:30 AM
News IconAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) set to announce results tomorrow - FinancialsTrend (NASDAQ:AGIO) - February 18 at 9:30 AM logoAgios Pharmaceuticals 4Q Loss Beats Street (AGIO) (NASDAQ:AGIO) - February 17 at 6:43 PM logoAgios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 (NASDAQ:AGIO) - February 17 at 6:43 PM logoAgios Pharmaceuticals 4Q Loss $1.48 Per Share (NASDAQ:AGIO) - February 17 at 6:43 PM logoAgios Pharmaceuticals Inc Earnings Call (Q4 2016) (NASDAQ:AGIO) - February 16 at 8:27 PM logoAgios Pharmaceuticals Inc Earnings Call (Q4 2016) (NASDAQ:AGIO) - February 16 at 8:27 PM logoBRIEF-Agios says cash, marketable securities were $573.6 mln as of Dec. 31 (NASDAQ:AGIO) - February 16 at 8:27 PM logoAGIOS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:AGIO) - February 16 at 8:27 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Results of Operations and Financial Condition (NASDAQ:AGIO) - February 16 at 8:27 PM
News IconAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) set to announce results tomorrow (NASDAQ:AGIO) - February 16 at 8:27 PM logo10-K: AGIOS PHARMACEUTICALS INC (NASDAQ:AGIO) - February 16 at 8:27 PM logoAgios Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:AGIO) - February 16 at 8:27 PM logoAgios Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:AGIO) - February 16 at 8:27 PM logo7:10 am Agios Pharma reports smaller than expected Q4 net loss; highlights key upcoming milestones (NASDAQ:AGIO) - February 16 at 8:27 PM logo7:10 am Agios Pharma reports smaller than expected Q4 net loss; highlights key upcoming milestones (NASDAQ:AGIO) - February 16 at 8:27 PM logoEdited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT (NASDAQ:AGIO) - February 16 at 8:27 PM
News IconIs The Sell-Side Predicting That Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Will Move Higher? - Winfield Review (NASDAQ:AGIO) - February 16 at 3:26 PM
News IconMarket Update: Watching Increased Volatility on Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Aiken Advocate (NASDAQ:AGIO) - February 16 at 3:26 PM logoAgios Pharmaceuticals reports 4Q loss (NASDAQ:AGIO) - February 16 at 3:26 PM logoAGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:AGIO) - February 16 at 3:26 PM logoAgios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:AGIO) - February 16 at 3:26 PM logoAgios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y (NASDAQ:AGIO) - February 16 at 3:26 PM
News IconAgios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones - EconoTimes (NASDAQ:AGIO) - February 16 at 7:12 AM
News IconAre Analysts Optimistic About Where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is Heading? - Winfield Review (NASDAQ:AGIO) - February 16 at 7:12 AM
News IconA look at Agios Pharmaceuticals, Inc. (AGIO)'s track record of earnings - Post Analyst (NASDAQ:AGIO) - February 16 at 7:12 AM logoDrug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More (NASDAQ:AGIO) - February 16 at 7:12 AM logoAgios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones (NASDAQ:AGIO) - February 16 at 7:12 AM logoQ4 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open (NASDAQ:AGIO) - February 16 at 7:12 AM
News IconStock Update: Focusing on Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Midway Monitor (NASDAQ:AGIO) - February 14 at 3:39 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:AGIO) - February 13 at 8:19 PM
News IconAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock ABR At 1.63 - Stock Observer (NASDAQ:AGIO) - February 12 at 8:25 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Records An Impact Score Of 50 - Investor Newswire (NASDAQ:AGIO) - February 12 at 3:24 PM logoAgios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store? (NASDAQ:AGIO) - February 10 at 3:52 PM logoAgios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017 (NASDAQ:AGIO) - February 9 at 3:24 PM
News IconWhat The Charts Are Saying About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Baxter Review (NASDAQ:AGIO) - February 7 at 8:45 PM
News IconMomentum Targets on Watch: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Aiken Advocate (NASDAQ:AGIO) - February 7 at 3:43 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) EPS Projection At $-1.18 - (NASDAQ:AGIO) - February 4 at 3:27 PM
News IconCan This Stock Gain Traction: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Prospect Journal (NASDAQ:AGIO) - January 31 at 1:07 AM
News IconStock Survey: Viewing Levels for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - The Tribune (NASDAQ:AGIO) - January 29 at 8:24 PM
News IconStock Perspective: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Earnings in View - Aiken Advocate (NASDAQ:AGIO) - January 29 at 3:23 PM
News IconVC Score In Focus for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - The Tribune (NASDAQ:AGIO) - January 29 at 1:42 AM
News IconWatching the Charts on Agios Pharmaceuticals Inc. (AGIO) - Springdale Times (NASDAQ:AGIO) - January 28 at 3:23 PM
News IconFollowing the Numbers on Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - The Tribune (NASDAQ:AGIO) - January 27 at 8:29 PM
News IconIndependence is a constant challenge for cancer drug startups (NASDAQ:AGIO) - January 27 at 3:26 PM


What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

13 brokers have issued 1 year target prices for Agios Pharmaceuticals' stock. Their predictions range from $45.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $63.90 in the next twelve months.

When will Agios Pharmaceuticals announce their earnings?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

  • According to Zacks Investment Research, "Agios is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders. Being a development-stage company, Agios depends heavily on Celgene for revenues, which it earns in the form of collaboration revenues. The collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. However, company also depends on Celgene for two of its pipeline candidates – enasidenib and AG-881. Agios’ progress with its pipeline has been impressive. Notably, most of the company's pipeline candidates are in mid and early stages of development and thus several years from entering the market, if at all. Stiff competition is another threat. Shares of the company have underperformed the Medical-Products industry in 2016. The company’s estimates have been going down lately ahead of its Q4 earning." (1/27/2017)

  • Cann analysts commented, "We are upgrading Agios Pharmaceuticals, a very high quality development-stage biotechnology company with an exceptional management team, from Perform to Outperform, with a $75 12- to 18-month price target." (1/17/2017)

  • Credit Suisse Group analysts commented, "We view this as positive proof of concept for the inhibition of mutIDH in the treatment of IDHmut glioma. We note AG-120 shows only limited brain penetration, and we view these data providing a positive read-through for AG-881’s development in this indication." (11/21/2016)

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.99%), Capital International Investors ** (10.00%), State Street Corp (2.95%), Capital Guardian Trust Co. (1.94%), Columbia Wanger Asset Management LLC (1.51%) and Janus Capital Management LLC (0.91%). Company insiders that own Agios Pharmaceuticals stock include Christopher Bowden, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley and Scott Biller.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Clarius Group LLC, Marshall Wace LLP, Asset Management One Co. Ltd., Guggenheim Capital LLC, Arrowpoint Asset Management LLC, Fiera Capital Corp and AQR Capital Management LLC. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley and Scott Biller.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Capital Guardian Trust Co., State Street Corp, Brown Advisory Inc., FMR LLC, Capital International Ltd. CA, Janus Capital Management LLC, Capital International Inc. CA and Oxford Asset Management.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agios Pharmaceuticals stock cost?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $50.40.

Agios Pharmaceuticals (NASDAQ:AGIO) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings History Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Dividend History Chart

Dividend Payments by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Last Updated on 2/22/2017 by Staff